Cargando…

Pharmacokinetics of bisphenol A in humans following dermal administration

BACKGROUND: Human exposures to bisphenol A (BPA) are widespread. The current study addresses uncertainties regarding human pharmacokinetics of BPA following dermal exposure. OBJECTIVE: To examine the absorption, distribution, metabolism and excretion of BPA in humans following dermal administration....

Descripción completa

Detalles Bibliográficos
Autores principales: Sasso, Alan F., Pirow, Ralph, Andra, Syam S., Church, Rebecca, Nachman, Rebecca M., Linke, Susanne, Kapraun, Dustin F., Schurman, Shepherd H., Arora, Manish, Thayer, Kristina A., Bucher, John R., Birnbaum, Linda S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210257/
https://www.ncbi.nlm.nih.gov/pubmed/32798798
http://dx.doi.org/10.1016/j.envint.2020.106031
_version_ 1784730127491399680
author Sasso, Alan F.
Pirow, Ralph
Andra, Syam S.
Church, Rebecca
Nachman, Rebecca M.
Linke, Susanne
Kapraun, Dustin F.
Schurman, Shepherd H.
Arora, Manish
Thayer, Kristina A.
Bucher, John R.
Birnbaum, Linda S.
author_facet Sasso, Alan F.
Pirow, Ralph
Andra, Syam S.
Church, Rebecca
Nachman, Rebecca M.
Linke, Susanne
Kapraun, Dustin F.
Schurman, Shepherd H.
Arora, Manish
Thayer, Kristina A.
Bucher, John R.
Birnbaum, Linda S.
author_sort Sasso, Alan F.
collection PubMed
description BACKGROUND: Human exposures to bisphenol A (BPA) are widespread. The current study addresses uncertainties regarding human pharmacokinetics of BPA following dermal exposure. OBJECTIVE: To examine the absorption, distribution, metabolism and excretion of BPA in humans following dermal administration. METHODS: We dermally administered deuterated BPA (d6-BPA) to 10 subjects (6 men and 4 women) at a dose of 100 μg/kg over a 12-hour period and conducted blood and urine analysis from the beginning of dosing through a three- or six-day period. We present time-course serum and urine concentrations of total and unconjugated (“free”) d6-BPA and used this information to calculate terminal half-life and area under the curve. RESULTS AND CONCLUSIONS: Detectable serum levels of total d6-BPA were observed at 1.4 h after the start of dosing, and a maximum serum concentration (C(max)) of 3.26 nM was observed. Free d6-BPA was detectable in serum 2.8 h after start of dermal administration, with C(max) of 0.272 nM. Beginning at approximately seven hours and continuing to 12 h (which corresponds to cessation of exposure), the concentration of free and total serum d6-BPA plateaued. The terminal half-lives of total d6-BPA and free d6-BPA in the body were 21.4 ± 9.81 h and 17.6 ± 7.69 h, respectively. Elimination from the body was rate-limited by kinetics in the dermal compartment. Free d6-BPA was a greater percentage of the area under the curve of total serum BPA (8.81%) compared to the0.56% observed in our previously published oral study. Recovery of total d6-BPA in urine was < 2% of the applied dose after six days. Analysis of the area under the curve for dermal and oral administration revealed that 2.2% of the dermal dose became systemically available. These data are in line with prior studies indicating how pharmacokinetics of BPA differ following oral and dermal exposures. Dermal exposure resulted in a longer apparent half-life and higher free:total d6-BPA ratio compared to oral.
format Online
Article
Text
id pubmed-9210257
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-92102572022-06-21 Pharmacokinetics of bisphenol A in humans following dermal administration Sasso, Alan F. Pirow, Ralph Andra, Syam S. Church, Rebecca Nachman, Rebecca M. Linke, Susanne Kapraun, Dustin F. Schurman, Shepherd H. Arora, Manish Thayer, Kristina A. Bucher, John R. Birnbaum, Linda S. Environ Int Article BACKGROUND: Human exposures to bisphenol A (BPA) are widespread. The current study addresses uncertainties regarding human pharmacokinetics of BPA following dermal exposure. OBJECTIVE: To examine the absorption, distribution, metabolism and excretion of BPA in humans following dermal administration. METHODS: We dermally administered deuterated BPA (d6-BPA) to 10 subjects (6 men and 4 women) at a dose of 100 μg/kg over a 12-hour period and conducted blood and urine analysis from the beginning of dosing through a three- or six-day period. We present time-course serum and urine concentrations of total and unconjugated (“free”) d6-BPA and used this information to calculate terminal half-life and area under the curve. RESULTS AND CONCLUSIONS: Detectable serum levels of total d6-BPA were observed at 1.4 h after the start of dosing, and a maximum serum concentration (C(max)) of 3.26 nM was observed. Free d6-BPA was detectable in serum 2.8 h after start of dermal administration, with C(max) of 0.272 nM. Beginning at approximately seven hours and continuing to 12 h (which corresponds to cessation of exposure), the concentration of free and total serum d6-BPA plateaued. The terminal half-lives of total d6-BPA and free d6-BPA in the body were 21.4 ± 9.81 h and 17.6 ± 7.69 h, respectively. Elimination from the body was rate-limited by kinetics in the dermal compartment. Free d6-BPA was a greater percentage of the area under the curve of total serum BPA (8.81%) compared to the0.56% observed in our previously published oral study. Recovery of total d6-BPA in urine was < 2% of the applied dose after six days. Analysis of the area under the curve for dermal and oral administration revealed that 2.2% of the dermal dose became systemically available. These data are in line with prior studies indicating how pharmacokinetics of BPA differ following oral and dermal exposures. Dermal exposure resulted in a longer apparent half-life and higher free:total d6-BPA ratio compared to oral. 2020-11 2020-08-13 /pmc/articles/PMC9210257/ /pubmed/32798798 http://dx.doi.org/10.1016/j.envint.2020.106031 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Article
Sasso, Alan F.
Pirow, Ralph
Andra, Syam S.
Church, Rebecca
Nachman, Rebecca M.
Linke, Susanne
Kapraun, Dustin F.
Schurman, Shepherd H.
Arora, Manish
Thayer, Kristina A.
Bucher, John R.
Birnbaum, Linda S.
Pharmacokinetics of bisphenol A in humans following dermal administration
title Pharmacokinetics of bisphenol A in humans following dermal administration
title_full Pharmacokinetics of bisphenol A in humans following dermal administration
title_fullStr Pharmacokinetics of bisphenol A in humans following dermal administration
title_full_unstemmed Pharmacokinetics of bisphenol A in humans following dermal administration
title_short Pharmacokinetics of bisphenol A in humans following dermal administration
title_sort pharmacokinetics of bisphenol a in humans following dermal administration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210257/
https://www.ncbi.nlm.nih.gov/pubmed/32798798
http://dx.doi.org/10.1016/j.envint.2020.106031
work_keys_str_mv AT sassoalanf pharmacokineticsofbisphenolainhumansfollowingdermaladministration
AT pirowralph pharmacokineticsofbisphenolainhumansfollowingdermaladministration
AT andrasyams pharmacokineticsofbisphenolainhumansfollowingdermaladministration
AT churchrebecca pharmacokineticsofbisphenolainhumansfollowingdermaladministration
AT nachmanrebeccam pharmacokineticsofbisphenolainhumansfollowingdermaladministration
AT linkesusanne pharmacokineticsofbisphenolainhumansfollowingdermaladministration
AT kapraundustinf pharmacokineticsofbisphenolainhumansfollowingdermaladministration
AT schurmanshepherdh pharmacokineticsofbisphenolainhumansfollowingdermaladministration
AT aroramanish pharmacokineticsofbisphenolainhumansfollowingdermaladministration
AT thayerkristinaa pharmacokineticsofbisphenolainhumansfollowingdermaladministration
AT bucherjohnr pharmacokineticsofbisphenolainhumansfollowingdermaladministration
AT birnbaumlindas pharmacokineticsofbisphenolainhumansfollowingdermaladministration